AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patients with castrate-resistant prostate cancer.
Synonyms:
S7040,AZD3514;
6-(4-{4-[2-(4-acetylpiperazin-1-yl)ethoxy]phenyl}piperidin-1-yl)-3-(trifluoromethyl)-7,8-dihydro[1,2,4]triazolo[4,3-b]pyridazine;
1-(4-(2-(4-(1-(3-(trifluoromethyl)-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)piperazin-1-yl)ethanone;
Chemical Properties:
Boiling point: 669.5±65.0 °C(Predicted)
density: 1.41±0.1 g/cm3(Predicted)
pka: 6.31±0.10(Predicted)
Androgen Receptor Inhibitors Related Products:
Chlormadinone acetate; Bicalutamide; Apalutamide; Galeterone; Cyproterone acetate; Spironolactone; ARV-110; Darolutamide; Megestrol Acetate; Clascoterone; RU-58841; Enzalutamide